Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott to acquire Sanofi Carpuject injectable system, multi-source line for about $200 mil.

Executive Summary

ABBOTT TO ACQUIRE SANOFI CARPUJECT INJECTABLE LINE FOR APPROXIMATELY $200 MIL. in a deal expected to close this summer, Abbott said April 29. The acquisition will give Abbott worldwide rights to Sanofi's Carpuject line of pre-filled, single-dose syringes. In addition to Carpuject, Abbott will obtain Sanofi's line of multi-source injectable drugs, including anesthetics such as Marcaine (bupivacaine), analgesics, central nervous system drugs and cardiovascular drugs. Sanofi's Primacor (milrinone lactate) and Inocor (amrinone lactate) injections are not included in the deal.
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS030165

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel